Personality may influence the response to apomorphine infusion in Parkinson’s disease patients
Objective: to evaluate the impact of personality on quality-of-life (QoL) amelioration after treatment by Continuous Subcutaneous Apomorphine Infusion (CSAI) in Parkinson’s disease (PD). Background: PD…A Phase 2 Randomized Clinical Trial of TAK-071, an Acetylcholine M1 Receptor Positive Allosteric Modulator, in Parkinson Disease with Cognitive Impairment
Objective: To study the safety and efficacy of TAK-071, an M1 positive allosteric modulator, in adults with Parkinson disease (PD) with increased risk for falls…Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data
Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial. Background: IPX203 is a novel extended-release,…The HIIT-Home4Parkinson’s study
Objective: This study aims to evaluate the practicality and utility of a novel, co-created home-based high-intensity interval training (HIIT) programme for people with Parkinson’s (PwP).…Interim results of a mixed method research-in-action study to evaluate and improve patient and public involvement within the EJS ACT-PD initiative
Objective: To improve patient and public involvement and engagement (PPIE) within EJS ACT-PD by evaluating members’ perceptions of PPIE through a mixed methods research-in-action study.…Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease
Objective: To assess predictability of “On” or “Off” motor states in patients (pts) with advanced Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: Pts with…Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants
Objective: Obtain patient feedback on experiences initiating and using continuous subcutaneous apomorphine infusion (CSAI). Background: Previously reported data from the ongoing InfusON study demonstrated that…Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease
Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease
Objective: We sought to determine whether fecal bile acids (BAs) could affect levodopa response assessed by levodopa challenge test (LCT) in patients with Parkinson’s disease…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 181
- Next Page »